AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 254 min read$CTNM

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

Original reporting
insidermonkey.com
Published Sep 25, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 12:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$CTNMBearishMed
01

Why it matters

The miss underscores the high risk of CNS drug development and may prompt re‑evaluation of partnership strategies.

02

Market read

Primary disclosure of a Phase 2 failure for a depression drug; material for biotech investors and may influence partner sentiment.

03

What to watch

Potential value in exploratory endpoints and future indications for PIPE-307.

Relevance 8/10Novelty 8/10Timing: today

Background

The article discusses the failed Phase 2 trial of JNJ-5120/PIPE-307, a muscarinic M1 receptor antagonist for major depressive disorder, and its implications for both Contineum Therapeutics and Johnson & Johnson.

Company-level read

Ticker impact

$CTNMBearishHigh confidence
Context

Contineum Therapeutics reported that its partnered depression drug missed the primary endpoint in a Phase 2 trial.

Expected impact

downward pressure in short term

Evidence & confidence

Phase 2 miss is a material setback for a biotech's pipeline and valuation.

$JNJBearishMedium confidence
Context

Johnson & Johnson is reviewing broader data after its partnered drug failed to meet efficacy goals in the Phase 2 study.

Expected impact

slight downside or neutral as impact is limited to a single partnership

Evidence & confidence

J&J's diversified portfolio buffers the effect, but the failure could affect sentiment on its biotech collaborations.

Market effects

Sector

Highlights risk in depression drug development, may affect other biotech peers.

Regional

U.S. biotech sector could see modest pullback.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If safety profile remains clean, the drug could still find a niche or be repurposed.

Key entities

  • Company
    Contineum Therapeutics

    Biotech developing PIPE-307 and other programs.

  • Company
    Johnson & Johnson

    Partnering with Contineum on the depression drug.

Read at source← All news

Related articles

SEP 25
$JNJHighAI 8/10

Johnson & Johnson Reports TREMFYA STAR Trial Results

Johnson & Johnson (JNJ) reported positive Phase 4 STAR trial results for TREMFYA in treating axial psoriatic arthritis. The drug met primary and major secondary endpoints, showing improvements in disease activity, axial symptoms, and MRI-measured inflammation at Week 24. The safety profile was consistent with previous findings. Detailed results will be presented at a future scientific congress.

grafa.com2 min
SEP 25
$JNJLow

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® (ciltacabtagene autoleucel) for early-line relapsed/refractory multiple myeloma achieved five-year treatment-free remission. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% five-year overall survival rate and 60.5-month median progression-free survival. The company suggests earlier treatment may increase long-term remission and disease control.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson (JNJ) reported positive results from the Phase 4 STAR study of TREMFYA (guselkumab) in patients with axial psoriatic arthritis (PsA). The drug met primary and major secondary endpoints, showing improvement in spinal pain, stiffness, and MRI-confirmed inflammation. JNJ aims to position TREMFYA as a first-line treatment for axial PsA, an area with significant unmet needs. Detailed results will be presented at an upcoming scientific congress.

prnewswire.com2 min
SEP 25
$JNJMedAI 8/10

Half of patients in a J&J study were alive without worsening myeloma five years after one infusion

Johnson & Johnson (JNJ) reported that 50% of patients in a Phase 2 study of CARVYKTI® for multiple myeloma were alive and progression-free five years after a single infusion. The study, presented at the International Myeloma Society Annual Meeting, showed a 69.2% overall survival rate and 60.5-month median progression-free survival. CARVYKTI is approved in 17 markets and has treated over 13,000 patients globally, according to the company.

stocktitan.net2 min